» Articles » PMID: 38338859

Mesenchymal Stem Cells from Familial Alzheimer's Patients Express MicroRNA Differently

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Feb 10
PMID 38338859
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the predominant form of dementia globally. No reliable diagnostic, predictive techniques, or curative interventions are available. MicroRNAs (miRNAs) are vital to controlling gene expression, making them valuable biomarkers for diagnosis and prognosis. This study examines the transcriptome of olfactory ecto-mesenchymal stem cells (MSCs) derived from individuals with the PSEN1(A431E) mutation (Jalisco mutation). The aim is to determine whether this mutation affects the transcriptome and expression profile of miRNAs and their target genes at different stages of asymptomatic, presymptomatic, and symptomatic conditions. Expression microarrays compare the MSCs from mutation carriers with those from healthy donors. The results indicate a distinct variation in the expression of miRNAs and mRNAs among different symptomatologic groups and between individuals with the mutation. Using bioinformatics tools allows us to identify target genes for miRNAs, which in turn affect various biological processes and pathways. These include the cell cycle, senescence, transcription, and pathways involved in regulating the pluripotency of stem cells. These processes are closely linked to inter- and intracellular communication, vital for cellular functioning. These findings can enhance our comprehension and monitoring of the disease's physiological processes, identify new disorder indicators, and develop innovative treatments and diagnostic tools for preventing or treating AD.

Citing Articles

Olfactory Ecto-Mesenchymal Stem Cells in Modeling and Treating Alzheimer's Disease.

Wang H, Dwamena A Int J Mol Sci. 2024; 25(15).

PMID: 39126059 PMC: 11313019. DOI: 10.3390/ijms25158492.


Molecular Morbidity Score-Can MicroRNAs Assess the Burden of Disease?.

Butler T, Davey M, Kerin M Int J Mol Sci. 2024; 25(15).

PMID: 39125612 PMC: 11312210. DOI: 10.3390/ijms25158042.


Molecular Mechanisms of Dementia 2.0.

Cantone M Int J Mol Sci. 2024; 25(13).

PMID: 39000213 PMC: 11241032. DOI: 10.3390/ijms25137110.

References
1.
Garcia G, Pinto S, Cunha M, Fernandes A, Koistinaho J, Brites D . Neuronal Dynamics and miRNA Signaling Differ between SH-SY5Y and Mutant iPSC-Derived AD Models upon Modulation with miR-124 Mimic and Inhibitor. Cells. 2021; 10(9). PMC: 8465877. DOI: 10.3390/cells10092424. View

2.
Zhan-Qiang H, Hai-Hua Q, Chi Z, Miao W, Cui Z, Zi-Yin L . miR-146a aggravates cognitive impairment and Alzheimer disease-like pathology by triggering oxidative stress through MAPK signaling. Neurologia (Engl Ed). 2023; 38(7):486-494. DOI: 10.1016/j.nrleng.2020.12.006. View

3.
Li S, Lei Z, Sun T . The role of microRNAs in neurodegenerative diseases: a review. Cell Biol Toxicol. 2022; 39(1):53-83. PMC: 9486770. DOI: 10.1007/s10565-022-09761-x. View

4.
Rudzinski L, Fletcher R, Dickson D, Crook R, Hutton M, Adamson J . Early onset familial Alzheimer Disease with spastic paraparesis, dysarthria, and seizures and N135S mutation in PSEN1. Alzheimer Dis Assoc Disord. 2008; 22(3):299-307. PMC: 2750842. DOI: 10.1097/WAD.0b013e3181732399. View

5.
Sierksma A, Lu A, Salta E, Vanden Eynden E, Callaerts-Vegh Z, DHooge R . Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology. Mol Neurodegener. 2018; 13(1):54. PMC: 6186090. DOI: 10.1186/s13024-018-0285-1. View